Insecticides Intrinsic Value
Insecticides intrinsic value. Insecticides (INSECTICID) median intrinsic value is ₹756.97 from 10 valuation models (range ₹161–₹1077), vs current price ₹538.30 — +40.6% upside (Trading Below Calculated Value), margin of safety 28.9%. Analyse INSECTICID shareholder distribution to track promoter, FII and institutional holdings.
INSECTICID Valuation Methods Summary — DCF, Graham Number & P/E
Insecticides intrinsic value across 10 models vs current price ₹538.30 — upside/downside and value range per method. For current market price and key ratios, visit Insecticides screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹926.40 | ₹741.12 - ₹1111.68 | +72.1% | EPS: ₹77.20, Sector P/E: 12x |
| Book Value Method | asset | ₹420.69 | ₹378.62 - ₹462.76 | -21.8% | Book Value/Share: ₹420.69, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹756.97 | ₹681.27 - ₹832.67 | +40.6% | Revenue/Share: ₹946.21, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹761.38 | ₹685.24 - ₹837.52 | +41.4% | EBITDA: ₹368.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹320.13 | ₹256.10 - ₹384.16 | -40.5% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹494.08 | ₹444.67 - ₹543.49 | -8.2% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹636.13 | ₹572.52 - ₹699.74 | +18.2% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1076.60 | ₹968.94 - ₹1184.26 | +100.0% | ROE: 18.4%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹841.38 | ₹757.24 - ₹925.52 | +56.3% | EPS: ₹77.20, BVPS: ₹420.69 |
| Dividend Yield Method | dividend | ₹161.49 | ₹145.34 - ₹177.64 | -70.0% | DPS: ₹2.00, Target Yield: 3.5% |
INSECTICID Intrinsic Value vs Market Price — All Valuation Models
Insecticides fair value range ₹161–₹1077 vs current market price ₹538.30 across 10 valuation models. Browse INSECTICID income statement for revenue, profit, balance sheet and cash flow data.
INSECTICID Intrinsic Value Analysis — Undervalued or Overvalued?
Insecticides median intrinsic value ₹756.97, current price ₹538.30 — Trading Below Calculated Value by 40.6%, margin of safety 28.9%.
What is the intrinsic value of INSECTICID?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Insecticides (INSECTICID) is ₹756.97 (median value). With the current market price of ₹538.30, this represents a +40.6% variance from our estimated fair value.
The valuation range spans from ₹161.49 to ₹1076.60, indicating ₹161.49 - ₹1076.60.
Is INSECTICID undervalued or overvalued?
Based on our multi-method analysis, Insecticides (INSECTICID) appears to be trading below calculated value by approximately 40.6%.
INSECTICID Financial Health — Key Ratios vs Industry Benchmarks
Insecticides financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 18.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.37x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
INSECTICID Cash Flow Quality — Operating & Free Cash Flow
Insecticides operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹100 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹94 Cr | ₹75 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹187 Cr | ₹164 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-11 Cr | ₹-54 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹135 Cr | ₹135 Cr | Positive Free Cash Flow | 8/10 |